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Abstract
An estimated 2.9 million new chlamydia infections occur in the United States each year. Among 
women, chlamydia can lead to serious adverse outcomes, including pelvic inflammatory disease 
and infertility. Chlamydia prevalence is highest among females aged 15–19 years. Despite long-
standing recommendations directed at young, sexually active females, screening remains 
suboptimal. Juvenile detention centers (JDCs) are uniquely situated to screen and treat high-risk 
adolescents. From 2009–2011, performance measure data on chlamydia screening coverage 
(proportion of eligible females screened) and positivity (proportion of females tested who were 
positive) were available from 126 geographically-dispersed JDCs in the United States. These 
facilities reported screening 55.2% of females entering the facilities (149,923), with a facility-
specific median of 66.4% (range: 0–100%). Almost half (44.4%) of facilities had screening 
coverage levels of 75–100%. This screening resulted in the detection of 12,305 chlamydial 
infections, for an overall positivity of 14.7% (facility-specific median = 14.9%, range: 0–36.9%). 
In linear regression analysis, chlamydia positivity was inversely associated with screening 
coverage: as coverage increased, positivity decreased. The burden of chlamydia in JDCs is 
substantial; facilities should continue to deliver recommended chlamydia screening and treatment 
to females and identify mechanisms to increase coverage.
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INTRODUCTION
Chlamydia is the most frequently occurring bacterial sexually transmitted infection (STI) in 
the United States (Satterwhite et al., 2013). Of the 2.9 million incident infections estimated 
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to occur annually, about 62% are among young males and females aged <26 years. An 
estimated 1 million infections occur in young females among whom chlamydia can lead to 
pelvic inflammatory disease, ectopic pregnancy, or infertility. Chlamydia prevalence is 
highest among sexually active females aged 15–19 years (6.8%) (CDC, 2011). In this age 
group, prevalence among young black females is almost four times the prevalence among 
young white females (16.2% versus 4.4%, respectively).
As the majority of chlamydial infections are asymptomatic, screening is necessary to 
identify infections (Farley et al., 2003). Due to the risk of sequelae and the high burden of 
infection, annual screening and treatment of sexually active women aged <26 years has been 
recommended for two decades (CDC, 1993, 2010). However, despite these strong 
recommendations, the proportion of females who are actually screened for chlamydia 
remains suboptimal (NCQA, 2012). Only 58% of sexually active young females seeking 
healthcare were screened in 2012 in Medicaid health maintenance organization (HMO) 
settings; only 45% were screened in commercial HMO settings. Screening coverage was 
lower among females aged 16–20 years compared to females aged 21–24 years (Medicaid 
HMO, 54.9% versus 63.4%).
Juvenile correctional settings represent an optimal, unique setting to deliver health care, 
particularly screening services, to an adolescent population generally at risk for adverse 
health events. Overall, adolescents do not frequently attend recommended well-care visits 
where routine preventive services, such as STI screening and treatment, would be delivered. 
Over a two-year period examining the Medicaid population, only 51% of adolescents aged 
14–16 years and 46% of those aged 17–20 years received a well-child exam (U.S. GAO, 
2009). In addition to a general lack of well-care visits among adolescents, young females in 
correctional settings are at high risk for chlamydia; in 2011, the overall chlamydia 
prevalence among females aged 12–18 years entering a select group of juvenile corrections 
facilities in the United States was 15.7% (CDC, 2012). Currently the Centers for Disease 
Control and Prevention (CDC) recommends universal screening of females at intake to 
juvenile correctional facilities (CDC, 2010).
The CDC implemented national performance measures in 2005 to improve the performance 
of sexually transmitted disease (STD) prevention programs. Priority interventions, such as 
chlamydia screening and treatment, in venues targeting priority populations (e.g., 
adolescents) were a key factor in developing and implementing these performance measures 
(Peterman et al., 2011). From 2005–2008, CDC performance measure data on chlamydia 
screening in juvenile detention centers showed that the proportion of females entering select 
juvenile detention centers who were screened for chlamydia increased from 55% to 58%. In 
2009, the CDC began collecting additional performance measure data on the proportion of 
females testing positive for chlamydia in juvenile detention centers, complimenting the 
screening coverage measure assessing the proportion of females screened for chlamydia in 
juvenile detention centers. To describe chlamydia screening coverage and chlamydia 
positivity and determine the yield of and rationale for continued universal chlamydia 
screening of young women in these settings, we analyzed these two performance measures 
across juvenile detention centers in the United States.
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METHODS
Participants
Performance measure data on screening coverage and chlamydia positivity among females 
entering juvenile detention centers have been reported by grantees funded through the 
Comprehensive STD Prevention Systems (CSPS) grant (http://www.cdc.gov/od/pgo/
funding/PS09-902.htm) since 2009. Grantees include the 50 states, Puerto Rico, the U.S. 
Virgin Islands, and large cities (Los Angeles, CA; San Francisco, CA; Chicago, IL; New 
York, NY; Philadelphia, PA; Baltimore, MD, and Washington, DC). All grantees were 
required to report performance measure data on chlamydia screening coverage and positivity 
for at least one juvenile detention center in their jurisdiction. Grantees were required to 
report data for each juvenile detention center that booked 500 or more females annually. If a 
grantee had no juvenile detention centers with this census, grantees were required to report 
on at least one juvenile detention facility of their choice in their jurisdiction.
Data Collection
Performance measure data on chlamydia screening and chlamydia positivity were required 
to be reported to CDC twice yearly (http://www.cdc.gov/std/program/performance-
measures.htm). Both chlamydia measures have been reported since 2009. Because required 
reporting of performance measures was discontinued in 2012, the analysis time frame is 
2009–2011, consisting of six half-year reporting periods. Measures were self-reported in 
aggregate format for each juvenile detention center, and data were not stratified by age or 
race/ethnicity. Data were entered into a standardized database designed to capture 
performance measure data and maintained at CDC.
For reporting purposes, the screening coverage performance measure was defined as the 
proportion of females admitted to the center who were tested for chlamydia (all ages). 
Testing could include tests specifically administered as screening tests (i.e., to asymptomatic 
individuals) and tests administered in a diagnostic capacity (i.e., to symptomatic individuals 
or individuals reporting risk factors suggestive of an infection, such as an infected partner). 
The numerator consisted of the number of females who were admitted and tested for 
chlamydia in the specified half-year time frame. The denominator was the total number of 
female admittees or bookings, including all females entering the juvenile detention center. 
Data may be duplicated; if a female entered a juvenile detention center more than one time 
during the reporting period or during multiple reporting periods, she was included in the 
denominator each time and may also be included in the numerator multiple times (if 
screening was performed multiple times).
Chlamydia positivity was defined as the number of females testing positive for chlamydia 
(numerator) divided by the number of females tested for chlamydia (denominator). Positivity 
performance measure data were reported for each juvenile detention center where screening 
coverage was reported. Theoretically, the denominator of the positivity performance measure 
should match the numerator of the screening coverage performance measure (number of 
females tested for chlamydia). However, no internal consistency checks were built into the 
performance measures collection tool and database. Grantees entered data directly for each 
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measure; therefore, it is possible that the positivity denominator did not perfectly match the 
screening coverage numerator. Other possible reasons that the denominators may not match 
include lost specimens, contaminated specimens, or inadequate specimens.
Aggregate data were collected as part of routine public health surveil-lance under the 
direction of the federal CSPS grant and were thus exempt from institutional review board 
(IRB) review.
Data Analysis
Data were analyzed using individual juvenile detention centers as the primary unit of 
analysis. To compare chlamydia screening coverage and positivity performance measures, 
aggregate reported data were combined for each juvenile detention facility. Numerators and 
denominators for each required half-year reporting period were summed by facility for the 
time frame from 2009 to 2011; up to six possible data points were included in the facility-
specific totals. Then, the overall proportion of females screened for chlamydia (screening 
coverage) and the overall proportion of females who tested positive for chlamydia 
(positivity) were calculated. Only facilities reporting at least one female eligible for 
screening, total screening coverage of >0%, and with data on both screening coverage and 
positivity were included in analyses. Screening coverage was split into two logical analysis 
categorizations to describe the proportion of females screened for chlamydia: 0–49% and 
50–100%; and, 0–24%, 25–49%, 50–74%, and 75–100%. Likewise, positivity was split 
using the mean value (<15%, ≥15%) and the quartile values (0–10%, 11–14%, 15–17%, 
>17%).
Screening coverage and positivity were analyzed at the facility level, as well as the regional 
levels. Differences in proportions were evaluated using chi-square tests. Continuous values 
were compared using t-tests (unequal variance). To assess the relationship between 
screening coverage and positivity, two analyses were conducted. First, a Pearson correlation 
coefficient was generated (r) comparing the proportion of women screened for chlamydia 
and the chlamydia positivity within each facility. Next, in a more granular approach, linear 
regression was conducted evaluating the relation of screening on positivity. Screening 
coverage was included in the model using an event/trials approach, in which the numerator 
was the number of women who tested positive for chlamydia and the denominator was the 
number of women who were tested for chlamydia. Modeling was conducted for the overall 
group of juvenile detention centers. Separate models were run for each of the four regions to 
examine potential geographical differences. Due to the nature of data collection, no 
additional covariates (other than region) were available for consideration in the modeling 
process. All analyses were performed using SAS (Version 9.1.3, Cary, NC).
RESULTS
From 2009–2011, a total of 166 juvenile detention centers reported performance measure 
data on chlamydia screening coverage or positivity among females. Of these, 126 facilities 
reported at least some data on both screening coverage and positivity and were eligible for 
analysis (75.9%).
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Facilities included in the analysis were present in 48 states, the District of Columbia, and 
Puerto Rico. On average, grantees reported data from 2.4 juvenile detention facilities 
(median: 2, range: 1–13, standard deviation [SD]: 2.2). About one-third of facilities were 
located in the West region (Table 1). Of the 126 facilities, 36 (28.6%) were required by the 
CDC to report data for each a half-year reporting period because the annual number of 
females eligible for screening (entering the facility) was 500 or greater. The vast majority of 
facilities reported data for the maximum number of reporting cycles (6 cycles); over 90% of 
facilities reported data for 5–6 reporting cycles. The median facility-specific total number of 
females eligible for screening over the course of the entire 3-year analysis period (2009–
2011) was 770, with a range of 8 to 9,457 females.
The 126 juvenile detention centers analyzed screened a total of 82,689 females from 2009–
2011, 55.2% of the total number of females entering the facilities (149,923). The highest 
number and overall proportion of females screened was in the West (Figure 1). The facility-
specific median level of screening coverage was 66.4% (range: 0–100%). Almost half 
(44.4%) of facilities had screening coverage levels of 75–100%; in 59.5% of facilities, the 
proportion of eligible females that were screened was 50% or greater (Table 1). Of the 126 
total juvenile detention centers, 23 (18.3%) reported a screening coverage of 95% or higher. 
On average, these 23 facilities screened 997 females from 2009–2011 (median: 570, range: 
29–4,009) and had a mean positivity of 13.6% (median: 14.0%, range: 3.2–20.7%).
Across all facilities, screening resulted in the detection of 12,305 chlamydial infections, for 
an overall positivity of 14.7% (facility-specific median = 14.9%, range: 0–36.9%). 
Chlamydia positivity was consistently high across all reporting juvenile detention centers; 
almost 80% of facilities reported a positivity of 11% or higher. The vast majority of facilities 
reported a chlamydia positivity of >3% (120 of 126 facilities, 95.2%). The six remaining 
facilities reported a positivity of 0%; four of these facilities tested fewer than 10 females. 
The highest overall regional positivity (17.1%) was in the in the Midwest (Figure 1).
When considering facilities with high screening coverage levels (50–100%) compared to 
facilities with low screening coverage levels (1–49%), no significant regional variations 
were seen (Table 2). Likewise, the mean number of females eligible for screening was 
similar between facilities with high and low levels of screening. Not surprisingly, facilities 
with high screening tested a higher absolute number of females for chlamydia. Facilities 
with low screening levels reported slightly higher chlamydia positivity among those women 
tested for chlamydia compared to facilities with high screening levels; however, this 
difference was not significant. The mean positivity of low screening facilities was 15.8% 
(SD = 8.0%), compared to the mean of 13.7% (SD = 5.0%) in facilities with high screening 
(p = 0.10). Of the 61 facilities reporting positivity of more than 15% (high positivity), 37.7% 
were located in the South (Table 2). Of the 65 facilities reporting positivity of 0–15% (low 
positivity), 46.2% were located in the West and 23.1% were located in the South (p = 0.01).
Analysis examining the correlation between overall screening coverage and positivity 
showed a weak correlation (r when = −0.16, p = 0.08). However, when considering all data 
(numerator and denominator), a significant relationship was seen: chlamydia positivity 
increased as screening coverage decreased (Figure 2). In crude linear regression, screening 
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coverage was inversely associated with positivity (Table 3). For each percentage point 
increase in screening coverage (e.g., increasing from 50% to 51% screening coverage), 
positivity decreased 0.37 percentage points (e.g., decreased from 20.0% to 19.63%). When 
stratifying by geographic region, the inverse linear relationship between screening coverage 
and positivity was evident in the South and West (p < 0.001 for each region); however, a 
significant linear relationship was not seen in the Midwest and Northeast.
DISCUSSION
In this convenience sample of juvenile detention centers from across the United States, over 
12,000 cases of chlamydia were diagnosed over the course of three years. Despite the large 
number of detected infections, many infections likely remained undetected due to an overall 
screening coverage level of only 55.2%.
Chlamydia remains an important public health concern, with young women bearing a 
disproportionate burden of the adverse outcomes resulting from infection. Chlamydia 
screening and treatment of young women is an important tool to address this issue, widely 
recommended, supported, and promoted by a number of professional medical organizations 
and governmental agencies (Maloney & Johnson, 2008). Juvenile detention centers are 
opportune settings to deliver recommended prevention services to an at-risk population of 
young, at-risk females. In the United States, there were an estimated 570,000 juvenile arrests 
of females (aged <18 years) in 2009 (U.S. DOJ, 2011). Many of these females are at 
increased risk of STIs due to sexual behaviors (e.g., early sexual debut, commercial sex 
work) as well as other risk factors (e.g., substance abuse) (Belenko et al., 2009). In a survey 
of incarcerated youth in a large, urban correctional facility, 90% of female adolescents 
reported using illegal drugs, 41% reported unprotected vaginal sex in the last month, and 
52% reported ever having unprotected sex while drunk or high (Teplin et al., 2003).
Among the subset of juvenile detention centers reporting performance measure data to the 
CDC from 2009–2011, the proportion of females entering facilities who were screened for 
chlamydia was only 56%, a suboptimal coverage level. Although this coverage is similar to 
females receiving care in health maintenance organizations (NCQA, 2012) and federally-
funded family planning clinics (Fowler et al., 2011), young females entering detention 
facilities are present in a controlled setting that can facilitate the delivery of on-site 
healthcare. Many of the juvenile detention facilities reported higher screening coverage: 56 
facilities (44.4%) had screening in the range of 75–100%, while 23 (18.3%) reported near-
perfect screening of females entering the facility (95–100%). These high-performing 
juvenile detention centers served a range of 29–4,009 females, demonstrating that facility 
size alone should not be a barrier to executing screening at a high level. The number of 
eligible females can also be considered a proxy measure for the complexity and scope of 
operations.
In examining the relationship between positivity and screening, the correlation between the 
two appeared to be weak. However, in linear regression analyses, an overall significant 
inverse relationship between chlamydia positivity and chlamydia screening was found. This 
finding appears to be driven by screening and positivity in the South and West, suggesting 
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that facilities in these geographic areas with low screening could be diagnostically testing 
adolescent females for chlamydia on the basis of signs or symptoms, or, possibly, applying 
some form of targeted screening. Thus, a smaller subset of the eligible population is tested 
(low screening coverage) with a high diagnostic yield (high chlamydia positivity). Despite a 
possible higher diagnostic yield, the substantial overall chlamydia positivity among both 
low- and high-screening facilities demonstrates an ongoing need to screen all eligible 
women, per current recommendations, and not just a subset (targeted screening).
Despite the success of some facilities in achieving high screening, over a third of facilities 
reported screening coverage levels of less than 50%. Barriers to universal screening at intake 
can occur at the patient-level and the provider-level, as well as the facility-level (Spaulding 
et al., 2013). For example, some females entering facilities decline screening. In a series of 
focus groups with delinquent youth, participants stated that fear of surreptitious drug testing 
might keep them from getting tested, along with fear of finding out that they were infected 
(Blake et al., 2003). Providers may be hesitant to screen at intake due to concerns over 
ability to treat the infection before the release, as some arrestees may be rapidly discharged 
(Spaulding et al., 2013). Additionally, facilities may consider costs (including staff time and 
cost of the test kits and treatment), confidentiality concerns, and limitations in the time 
available during the intake process prohibitive to universal screening (Belenko et al., 2009). 
One way to improve screening coverage is to integrate chlamydia screening into a 
comprehensive health assessment. For example, urine used for pregnancy or drug testing 
could also be used for the chlamydia screening (Spaulding et al., 2013). Additionally, 
correctional facilities may find it beneficial to partner with local public health facilities to 
facilitate timely treatment and ensure compliance with confidentiality and reporting laws 
(Belenko et al., 2009; Miller et al., 2009).
High chlamydia positivity in juvenile detention centers has been well demonstrated. 
Consistent with other findings, the median positivity of 14.8% in the 126 facilities reporting 
performance measure data was much higher than prevalence in the general population of 
adolescent females (estimated to be about 4% in 2008) (Datta et al., 2012), higher than 
positivity among young women screened in family planning clinics (median positivity of 
9.8% in 2011) (CDC, 2012), and higher than prevalence among female entrants to the 
National Job Training Program, a vocational program for socioeconomically disadvantaged 
young adults (10.4% in 2011) (CDC, 2012). The CDC currently recommends that emphasis 
be placed on screening and treating young women in venues where chlamydia positivity 
≥3%, a positivity level where chlamydia screening is considered to be cost-effective 
(Marrazzo et al., 1997). Only six facilities analyzed had a positivity of <3%, suggesting that 
chlamydia screening in juvenile detentions should remain a critical component to national 
chlamydia prevention efforts. Screening in these settings presents a cost-effective 
opportunity to deliver needed healthcare services to an at-risk population and may have the 
potential to decrease chlamydia prevalence in the surrounding communities (Owusu-Edusei 
et al., 2013).
Our study had several limitations. Data were reported in aggregate form, limiting the scope 
of the analysis to only summary-level information, and we were not able to investigate 
differences in screening coverage or positivity by race/ethnicity and age. Likewise, 
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information on the proportion of females diagnosed with chlamydia who were treated was 
not available. While efforts were made to standardize data based on performance measure 
case definitions, some variation in data sources and methods used to generate the self-
reported performance measure data could have occurred. The sample included in our 
analysis was a convenience sample. However, most facilities included in our analysis 
consistently reported data over the six time frames that were included, suggesting the 
presence of a standardized reporting procedure. While some level of reporting was required 
of all grantees, and some high-volume facilities were required to report (36 facilities 
booking 500 or more females annually, 28.6% of the sample), the sample of juvenile 
detention centers included may not have been representative of all facilities. In 2008, 734 
facilities defining themselves as juvenile detention centers reported holding juvenile 
offenders (male and females) (U.S. DOJ, 2012); in our study, 126 facilities were included, 
roughly 17% of all facilities in the United States.
Our analysis demonstrates high chlamydia positivity among females entering juvenile 
detention settings, supporting universal screening and treatment of females at entry per 
current recommendations. While high screening coverage is feasible, as indicated by the 
44% of facilities with >75% coverage and the 18% of facilities with >95% coverage, many 
facilities had suboptimal screening coverage. Identification and amelioration of barriers to 
screening in juvenile detention centers can enhance screening and treatment of women 
infected with chlamydia.
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FIGURE 1. 
Chlamydia screening and positivity in juvenile detention centers, by region, United States, 
2009–2011.
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FIGURE 2. 
Proportion of females screened for chlamydia and corresponding chlamydia positivity, 
juvenile detention centers, United States, 2009–2011. Each set of two bars (gray and black) 
represent the proportion of females screened for chlamydia and the chlamydia positivity in a 
single juvenile detention center. The horizontal line represents the modeled linear 
relationship between the proportion of women screened for chlamydia and the proportion of 
women testing positive (positivity).
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TABLE 1
Juvenile Detention Centers Reporting Data on Chlamydia Screening Coverage and Positivity, United States, 
2009–2011
Number of facilities
(n = 126)
Region, %
 Midwest 28 (22.2)
 Northeast 16 (12.7)
 South 38 (30.2)
 West 43 (34.1)
 Puerto Rico 1 (0.8)
Reporting required,* %
 Yes 36 (28.6)
 No 90 (71.4)
Number of half-year reporting cycles, %
 1 2 (1.6)
 2 2 (1.6)
 3 1 (0.8)
 4 6 (4.8)
 5 22 (17.5)
 6 93 (73.8)
 Mean number of females eligible for screening (median) 1,190 (770)
Proportion screened, %
 0–24 25 (19.8)
 25–49 26 (20.6)
 50–74 19 (15.1)
 75–100 56 (44.4)
 Mean number of females tested for chlamydia (median) 663 (313)
Proportion positive, %
 0–10 29 (23.0)
 11–14 36 (28.6)
 15–17 28 (22.2)
 > 17 33 (26.2)
*
Mean number of eligible females per year ≥ 500.
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TABLE 2
Screening Coverage and Positivity in Juvenile Detention Centers, United States, 2009–2011
Facility screening coverage
0–49%
(n = 51)
50–100%
(n = 75) p-Value
Region,* % 0.22
 Midwest 13 (25.5) 15 (20.0)
 Northeast 3 (5.9) 13 (17.3)
 South 14 (27.5) 24 (32.0)
 West 21 (41.2) 22 (29.3)
 Mean number of females eligible for screening (median) 1,262 (792) 1,141 (749) 0.66
 Mean number of females tested for chlamydia (median) 268 (194) 932 (582) < 0.01
 Proportion positive, % 0.03
 0–10 11 (21.6) 18 (24.0)
 11–14 9 (17.7) 27 (36.0)
 15–17 11 (21.6) 17 (22.7)
 > 17 20 (39.2) 13 (17.3)
Facility chlamydia positivity
0–15%
(n = 65)
> 15%
(n = 61) p-Value
Region,* % 0.01
 Midwest 9 (13.9) 19 (31.2)
 Northeast 10 (15.4) 6 (9.8)
 South 15 (23.1) 23 (37.7)
 West 30 (46.2) 13 (21.3)
 Mean number of females eligible for screening (median) 898 (574) 1,501 (960) 0.02
 Mean number of females tested for chlamydia (median) 633 (335) 695 (291) 0.67
 Proportion screened, % 0.03
 0–24 7 (10.8) 18 (29.5)
 25–49 13 (20.0) 13 (21.3)
 50–74 9 (13.9) 10 (16.4)
 75–100 36 (55.4) 20 (32.8)
*One facility in Puerto Rico reported a screening coverage level of 50–100% and a positivity of 0–15%.
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TABLE 3
Linear Regression Parameter Estimates: Chlamydia Screening Coverage and Positivity, United States, 2009–
2011
Model Parameter estimate 95% CI p-Value
Overall −0.37 −0.44, −0.29 < 0.001
Midwest −0.11 −0.29, 0.06 0.203
Northeast −0.08 −0.31, 0.16 0.523
South −0.58 −0.71, −0.46 < 0.001
West −0.31 −0.43, −0.19 < 0.001
CI = confidence interval.
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